This page has regimens and guidelines that are not specific to any one type of cancer. For disease-specific regimens and guidelines, please go to the following pages:

Section editor
Seema Nagpal, MD
Stanford University
Palo Alto, CA, USA

LinkedIn
Last updated on 2024-07-23:
1 regimens on this page
1 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.


ASCO/SNO/ASTRO




NCCN


All lines of therapy

Whole brain irradiation

WBRT: Whole-Brain Radiation Therapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Knisely et al. 2007 (RTOG 0118) 2002-2004 Phase 3 (C) Thalidomide & WBRT Did not meet primary endpoint of OS

Radiotherapy

One course

References

  1. RTOG 0118: Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):79-86. Epub 2007 Dec 31. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00033254